RxDoctor Payments DataLook up a doctor →

Walter Evans, MD

Neurology · Florence, SCNPI 1871609388

Payments from drug & device makers

$20,595in general payments, 2019–2025

Across 1,269 payments — averaging $16.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Biogen$2K
  • EMD Serono, Inc.$1K
  • Sanofi$950
  • Novartis$947
  • plus $12K from 54 others

What the payments were for

  • Speaking & faculty fees$1791%
  • Food & beverage$20,35199%
  • Education$650%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.113$1,995
Teva Pharmaceuticals USA, Inc.166$1,909
Biogen92$1,548
EMD Serono, Inc.68$1,063
Sanofi55$950
Novartis51$947
SK Life Science, Inc.47$835
Eisai Inc.50$828
AbbVie(2 entities)71$778
Acadia Pharmaceuticals Inc37$724
AstraZeneca(2 entities)35$708
Amgen(2 entities)32$615
Pfizer33$527
Neurocrine Biosciences, Inc.30$428
Lilly USA, LLC26$428
Mallinckrodt Hospital Products Inc.23$418
Bristol Myers Squibb27$400
Supernus Pharmaceuticals, Inc.31$379
Genentech USA, Inc.18$309
Lundbeck LLC17$296
Johnson & Johnson(2 entities)16$288
Jazz Pharmaceuticals Inc.16$282
Acorda Therapeutics, Inc15$271
Argenx US, Inc.14$269
CSL Behring12$250
MDD US Operations, LLC16$242
Amneal Pharmaceuticals LLC14$236
Akcea Therapeutics, Inc.8$231
Kyowa Kirin, Inc.14$227
Harmony Biosciences LLC10$194
Otsuka America Pharmaceutical, Inc.9$185
Catalyst Pharmaceuticals, Inc.8$157
Takeda Pharmaceuticals U.S.A., Inc.8$144
Alnylam Pharmaceuticals Inc.8$141
Neurelis, Inc.7$128
Scilex Pharmaceuticals Inc.5$118
Biohaven Pharmaceuticals, Inc.9$112
Grifols USA, LLC4$85
TG Therapeutics, Inc.4$84
Upsher-smith Laboratories LLC3$80
Amylyx Pharmaceuticals, Inc.3$76
Sumitomo Pharma America, Inc.4$71
Mallinckrodt Enterprises LLC6$67
Sanofi-aventis U.S. LLC4$64
Axsome Therapeutics, Inc.3$55
Livanova USA, Inc.3$50
Adamas Pharmaceuticals, Inc.3$50
Tanabe Pharma America, Inc.3$47
Banner Life Sciences, LLC3$45
Biohaven Pharmaceutical Holding Company Ltd.2$41
Zogenix Inc.2$34
Vanda Pharmaceuticals Inc.1$27
Arbor Pharmaceuticals, Inc.1$21
Aquestive Therapeutics, Inc.1$20
Bausch Health US, LLC1$19
Merck1$18
Cala Health, Inc.1$16
Avadel CNS Pharmaceuticals, LLC1$15
Avion Pharmaceuticals1$15
Alfasigma USA, Inc.1$14

How this compares

$20,595 in reported general payments places this provider in the 75th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$147,548
Medicare patients
387
Services billed
1,190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4677$663,079
Kesimpta PenOfatumumab66$626,626
GammakedImmune Globul G/Gly/Iga Avg 4643$441,732
BriviactBrivaracetam248$365,009
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5035$346,916
AustedoDeutetrabenazine25$317,309
Austedo XrDeutetrabenazine30$254,818
IngrezzaValbenazine Tosylate30$243,121
VumerityDiroximel Fumarate23$220,923
OctagamImmun Globg(Igg)/Malt/Iga Ov5012$163,194
EpidiolexCannabidiol (Cbd)23$143,082
AubagioTeriflunomide15$137,383
TecfideraDimethyl Fumarate12$113,914
TysabriNatalizumab13$106,675
PlegridyPeginterferon Beta-1a12$102,688

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$85$663,07977 claims
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$1,909$572,12655 claims
BiogenVumerity, Tecfidera, Tysabri, Plegridy$1,548$544,19960 claims
UCB, Inc.Briviact, Neupro$1,995$385,480266 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$144$346,91635 claims
Neurocrine Biosciences, Inc.Ingrezza$428$243,12130 claims
PfizerOctagam, Nurtec Odt$527$236,46764 claims
SanofiAubagio$950$137,38315 claims
Eisai Inc.Fycompa$828$94,27875 claims
AbbVieUbrelvy, Qulipta$778$80,27365 claims
Kyowa Kirin, Inc.Nourianz$227$69,17034 claims
SK Life Science, Inc.Xcopri$835$54,16947 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 270 neurology providers in South Carolina.

Other neurology in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →